Learn More About Specifically Targeting the ABL Myristoyl Pocket (STAMP) in CML
Bold Science: Transforming Lives, Striving for Cures
Reimagining Cancer and Blood Disorders
Novartis is reimagining medicine to improve people's lives. We use innovative science and digital technologies to create transformative treatments. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines. About 110,000 people of more than 140 nationalities work at Novartis.


View our broad research portfolio with innovative compounds in all phases of development.

Focus Areas
Focus Areas
Malignant Hematology
Malignant Hematology
Non-Malignant Hematology
Non-Malignant Hematology
Our 4 Bold Approaches to Cancer Treatment
Our 4 Bold Approaches to Cancer Treatment
Reimagining Cancer & Blood Disorders
Novartis is uniquely positioned to lead the next wave of novel investigational treatments through our strengths in 4 therapeutic platforms: targeted therapy, radioligand therapy, cell & gene therapy, and immunotherapy.
Proud of Our Bloodline
Proud of Our Bloodline
At Novartis, we are committed to the pursuit of cutting-edge medicines and are working to transform what it means to live with blood cancers and serious blood disorders.